Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Follow-Up Questions
Who is the CEO of Assembly Biosciences Inc?
Mr. Jason Okazaki is the President of Assembly Biosciences Inc, joining the firm since 2020.
What is the price performance of ASMB stock?
The current price of ASMB is $22.27, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Assembly Biosciences Inc?
Assembly Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Assembly Biosciences Inc market cap?
Assembly Biosciences Inc's current market cap is $295.3M
Is Assembly Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Assembly Biosciences Inc, including 4 strong buy, 5 buy, 1 hold, 0 sell, and 4 strong sell
